Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Adaptive Biotechnologies

15/12/2025 13:13

Dec 15 (Reuters) - Adaptive Biotechnologies ADPT.O said on Monday it has signed two non-exclusive deals with Pfizer PFE.N to support research in rheumatoid arthritis and other immune-related diseases.

     Adaptive said it will earn up to $890 million, including upfront fees and milestone payments tied to research progress, product development and sales.

 (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Krishna Chandra Eluri)

 ((Padmanabhan.Ananthan@thomsonreuters.com;))